BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumours
June 6, 2025Research and Development BioNTech, Oncology, bispecific antibody treatment, bristol myers squibb, oncology, partnership
BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise BNT327, BioNTech’s bispecific antibody, to …
Roche’s Evrysdi tablet approved in EU for spinal muscular atrophy
June 5, 2025Research and Development European Commission, Evrysdi, Neurology, Roche, european union, neuromuscular condition, spinal muscular atrophy (SMA)
Roche has received approval from the European Commission for a new tablet formulation of Evrysdi (risdiplam), marking the first and …
Study links COVID-19 and some vaccines to increased risk of rare neurological condition
June 5, 2025Medical Communications, Medical Education, Medical/ Scientific Writing, Research and Development COVID-19, COVID-19 vaccine, Guillain-Barré Syndrome (GBS), Neurology, Virology, adenoviral vector vaccines, mRNA-based vaccines, medical study, neurological condition
An international study has found an increased risk of Guillain-Barré syndrome (GBS) following SARS-CoV-2 infection and after vaccination with adenoviral …
Brenntag acquires mcePharma to expand GMP capabilities in biopharma services
June 5, 2025Manufacturing and Production, Mergers and Acquisitions Brenntag Specialities, Corporate, acquisition, continuous monitoring platform (CMP), mcePharma
Brenntag Specialties has acquired Czech-based mcePharma, strengthening its position in the pharma and biopharma industries through expanded continuous monitoring platform …
EU regulatory momentum could catalyse clinical trial innovation
June 5, 2025Regulatory Affairs, Research and Development AI, Corporate, EU regulation, Hospital Management, Pharmacy, Veeva Systems
Dr Werner Engelbrecht at Veeva Systems discusses how compliance can be turned into a competitive advantage with connected platforms and …
NIPRO introduces LiniXia water treatment system for dialysis clinics
June 4, 2025Research and Development European Renal Association (ERA) Congress, LiniXia, LiniXia PRO, NIPRO, Nephrology, dialysis clinics, water treatment
Japan-based biopharma, NIPRO, has launched LiniXia, a new reverse osmosis (RO) water treatment system for haemodialysis. It was unveiled at …
Astellas selects Veeva Vault CRM as global commercial platform
June 4, 2025Business Services, Technical Consultancy Astrellas, Corporate, Customer Relationship Management (CRM), Pharmacy, Vault CRM, Veeva Vault CRM, business services, cloud software
Astellas has selected Veeva Vault CRM as its global customer relationship management (CRM) platform, with Veeva China CRM deployed specifically …
Evosep launches high-throughput proteomics platform Evosep Eno
June 4, 2025Business Services, Mergers and Acquisitions, Research and Development, Translation Services Evosep, Pharmacy, biotech platform
Evosep has launched Evosep Eno, a new high-throughput separation platform designed to support next-generation workflows in liquid chromatography-mass spectrometry (LC-MS)-based …
LEO Pharma initiates phase 2a trial of delgocitinib cream for rare skin condition
June 3, 2025Research and Development Dermatology, LEO Pharma, Skin, clinical trial, delgocitinib cream, rare skin condition
LEO Pharma has initiated a phase 2a trial investigating delgocitinib cream in adults with mild-to-severe palmoplantar pustulosis (PPP). The DELTA …
Sanofi to acquire Blueprint, advancing therapy for rare immunological diseases
June 3, 2025Mergers and Acquisitions, Research and Development Blueprint Medicines, Immunology, Rare Diseases, Sanofi, advanced systemic mastocytosis (ASM), indolent systemic mastocytosis (ISM), rare immunological diseases
Sanofi and Blueprint Medicines Corporation, a US biopharma, have entered into an agreement under which Sanofi will acquire Blueprint. This …
New CAR T Vision Coalition and roadmap report to launch at ASCO aims to double patients treated with CAR T-cell therapy by 2030
June 3, 2025Research and Development American Society of Clinical Oncology, CAR T Vision, CAR T-cell therapy, International Myeloma Foundation, Kite, Leukemia & Lymphoma Society, Oncology, blood cancer
For people living with aggressive blood cancers, CAR T-cell therapy offers hope for a longer, healthier life, and for some, …
Teen band 1Type releases single to raise awareness of type 1 diabetes
May 30, 2025Medical Communications, Medical Education 1Type, Diabetes, Rise Up, Sanofi, Stagecoach Performing Art, autoimmune type 1 diabetes
Four teenagers living with autoimmune type 1 diabetes (aT1D) have released a single aimed at raising awareness of the condition …
Gene Weaver awarded Gates Foundation grant for programmable gene insertion platform
May 30, 2025Medical Communications, Research and Development Bill and Melinda Gates Foundation, Gene Weaver, Oncology, Pharmacy, Rare Diseases, funding, gene editing
UK-based biotech Gene Weaver has received $515,000 from the Bill and Melinda Gates Foundation to advance its programmable gene insertion technology …
Ochre Bio appoints Elaine Sullivan as senior independent non-executive director
May 30, 2025Research and Development Infections and infestations, Ochre Bio, Oncology, RNA therapeutics, Rare Diseases, appointment, senior independent non-executive director
Ochre Bio has appointed Elaine Sullivan as senior independent non-executive director. She joins the Oxford-based RNA therapeutics company with a …
NICE recommends mirikizumab (Omvoh â–¼) for previously treated moderately to severely active Crohn’s disease 1
May 30, 2025Research and Development Crohn’s disease, Eli Lilly and Company, Gastrointestinal tract, Medicines and Healthcare products Regulatory Agency (MHRA)(, NHS England and Wales, National Institute for Health and Care Excellence (NICE), Omvoh, inflammatory bowel disease (IBD), mirikizumab
In the Phase 3 VIVID-1 trial, patients treated with mirikizumab experienced significant improvement in clinical remission and endoscopic response at …
DEBRA Research and Dermaliq Therapeutics collaborate to advance treatment for rare skin disorder
May 29, 2025Research and Development DEBRA Research, Dermaliq Therapeutics, Dermatology, epidermolysis bullosa, non-profit organisation, skin disorders
Global non-profit organisation, DEBRA Research, and clinical dermatology company, Dermaliq Therapeutics, have announced a collaboration to advance drug development for …
Ryvu Therapeutics appoints Justyna Żółtek to management board
May 29, 2025Medical Communications, Research and Development Oncology, Ryvu Therapeutics, chief people officer, human resources, management board, oncology
Ryvu Therapeutics has promoted Justyna Żółtek, chief people officer, to its management board. The appointment reflects the company’s focus on …
Neogap receives approval to administer full dose in cell therapy trial for colorectal cancer
May 28, 2025Research and Development Neogap, Oncology, Swedish Medical Products Agency, colorectal cancer
Neogap Therapeutics has received regulatory approval from the Swedish Medical Products Agency to administer the full dose of its investigational …
TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform
May 28, 2025Mergers and Acquisitions Cell and Gene Therapy (CGT), Corporate, Juno GmbH, TQ Therapeutics, juno therapeutics
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share purchase agreement. Juno …
UK Researcher Wins Prestigious IBSA Foundation Fellowship for Pioneering Dermatology Study
May 28, 2025Medical Communications, Research and Development Dermatology, IBSA Foundation Fellowship, Institut Biochimique SA (IBSA), Masami Ando Kuri, Milan Italy, Wellcome Sanger Institute, dermatology
Masami Ando Kuri from the Wellcome Sanger Institute named one of six global winners of the 2024 IBSA Foundation Fellowships. …
Latest content
FibroFind appoints Lee Borthwick as CEO
